Synergizing sodium-dependent glucose transporter inhibitors with dipeptidyl-peptidase 4 inhibitor and metformin: a novel approach to diabetes management in India
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20250018Keywords:
Diabetes management, FDC, HCPs, Safety profile, Glycemic control, Cardio-renal outcomes, Indian populationAbstract
Background: The rising prevalence of diabetes in India necessitates effective and targeted management strategies. This article explores the efficacy of synergistic action of key antidiabetic agents, including metformin, sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, and dipeptidyl-peptidase-4 (DPP-4) inhibitors, in a fixed dose combination.
Methods: The current survey obtained the opinion of the health care professionals (HCPs) on the benefits and significance of the triple fixed dose combinations (FDCs) of dapagliflozin, sitagliptin, and metformin in type 2 diabetes mellitus (T2DM) management.
Results: The poll indicates that ~97% of the healthcare practitioners agreeing on the importance of achieving better time in range with the FDC and the potential benefits of early initiation of the FDC for improved glycemic control and cardio-renal outcomes. Majority of HCPs (77%) express confidence in the safety profile of the combination in T2DM. Almost all (99%) of the HCPs agree on the need for collating real-world data from HCPs to understand the effectiveness of FDC in India and for devising evidence based strategies.
Conclusions: The triple FDC of dapagliflozin, sitagliptin, and metformin stands out as a promising approach for diabetes management. The study also underscores the importance of conducting extensive, large scale real-world studies to gather more data, contributing to evidence based strategies for diabetes management in the Indian population.
Metrics
References
Mathur P, Leburu S, Kulothungan V. Prevalence, awareness, treatment and control of diabetes in India from the countrywide national NCD monitoring survey. Front Public Health. 2022;10:748157. DOI: https://doi.org/10.3389/fpubh.2022.748157
Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-89. DOI: https://doi.org/10.1016/S2213-8587(23)00119-5
Joseph LM, Berry D, Jessup A. Management of type 2 diabetes in Asian Indians: a review of the literature. Clin Nurs Res. 2015;24(2):188-210. DOI: https://doi.org/10.1177/1054773814531600
Nisar MU, Asad A, Waqas A, Ali N, Nisar A, Qayyum MA, et al. Association of diabetic neuropathy with duration of type 2 diabetes and glycemic control. Cureus. 2015;7(8):e302. DOI: https://doi.org/10.7759/cureus.302
MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes. 2017;8(5):172. DOI: https://doi.org/10.4239/wjd.v8.i5.172
Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636-43. DOI: https://doi.org/10.1007/s00125-011-2404-1
Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B, et al. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005;59:1345-55. DOI: https://doi.org/10.1111/j.1742-1241.2005.00674.x
Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450. DOI: https://doi.org/10.4103/jfmpc.jfmpc_843_20
Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95. DOI: https://doi.org/10.2337/db09-9028
Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther. 2022;13(5):1097-114. DOI: https://doi.org/10.1007/s13300-022-01219-x
Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care. 2021;44(2):549-55. DOI: https://doi.org/10.2337/dc20-1862
Takuma K, Fuchigami A, Shigiyama F, Kumashiro N, Hirose T. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study. Diabetes Obes Metab. 2023;25(8):2131-41. DOI: https://doi.org/10.1111/dom.15089
Jabbour SA, Hardy E, Sugg J, Parikh S; for the Study 10 Group. Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2014;37(3):1097-1114. DOI: https://doi.org/10.2337/dc13-0467
Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther. 2011;13(7):699-703. DOI: https://doi.org/10.1089/dia.2011.0025
Kasina SVSK, Baradhi KM. Dipeptidyl Peptidase IV (DPP IV) Inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.
Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, et al. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Adv Ther. 2023;40(7):3227-46. DOI: https://doi.org/10.1007/s12325-023-02523-z
Coordinators PP, Kumar H, Pandit K, Coordinators AM, Jacob J, Bhansali A, et al. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):2. DOI: https://doi.org/10.4103/2230-8210.293612
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, et al. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. Diabetes Ther. 2020;11(11):2465-76. DOI: https://doi.org/10.1007/s13300-020-00926-7
Lingvay I, Beetz N, Sennewald R, Schuler-Metz A, Bertulis J, Loley C, et al. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med. 2020;132(4):337-45. DOI: https://doi.org/10.1080/00325481.2020.1750228
Tinahones FJ, Gallwitz B, Nordaby M, Götz S, Maldonado‐Lutomirsky M, Woerle HJ, et al. Linagliptin as add‐on to empagliflozin and metformin in patients with type 2 diabetes: two 24‐week randomized, double‐blind, double‐dummy, parallel‐group trials. Diabetes Obes Metab. 2017;19(2):266-74. DOI: https://doi.org/10.1111/dom.12814
DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-93. DOI: https://doi.org/10.2337/dc14-2364
Downloads
Published
How to Cite
Issue
Section
